{"nctId":"NCT00004259","briefTitle":"Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas","startDateStruct":{"date":"2000-06"},"conditions":["Brain and Central Nervous System Tumors"],"count":230,"armGroups":[{"label":"Radiation therapy + temozolomide (TMZ)","type":"EXPERIMENTAL","interventionNames":["Drug: TMZ 200mg/m2","Radiation: radiation therapy"]},{"label":"RT + BCNU/CCNU","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: BCNU 80mg/m2","Radiation: radiation therapy","Drug: CCNU"]},{"label":"Pilot Arm #1: RT+TMZ+BCNU","type":"EXPERIMENTAL","interventionNames":["Radiation: radiation therapy","Drug: BCNU 200mg/m2","Drug: TMZ 150mg/m2 six 6-week cycles"]},{"label":"Pilot Arm #2: RT+TMZ+BCNU","type":"EXPERIMENTAL","interventionNames":["Radiation: radiation therapy","Drug: BCNU 150mg/m2","Drug: TMZ 150mg/m2 six 8-week cycles"]}],"interventions":[{"name":"BCNU 80mg/m2","otherNames":[]},{"name":"TMZ 200mg/m2","otherNames":[]},{"name":"radiation therapy","otherNames":[]},{"name":"CCNU","otherNames":[]},{"name":"BCNU 150mg/m2","otherNames":[]},{"name":"BCNU 200mg/m2","otherNames":[]},{"name":"TMZ 150mg/m2 six 6-week cycles","otherNames":[]},{"name":"TMZ 150mg/m2 six 8-week cycles","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Histologically proven unifocal anaplastic astrocytoma or mixed gliomas, including the following:\n\n  * Anaplastic astrocytoma\n  * Mixed oligodendroglial/astrocytic tumors\n\n    * Oligodendroglial component must be no greater than 25%\n* No vascular proliferation and necrosis\n* Increased cellularity, pleomorphism, and nuclear atypia allowed\n* No tumor predominantly located in the posterior fossa (i.e., brainstem or cerebellum)\n* Patients with prior biopsy proven low grade astrocytoma who now have anaplastic astrocytoma and have had no prior radiotherapy or chemotherapy also eligible\n* Study therapy must begin within 6 weeks of diagnosis\n* No spinal cord tumors, spinal drop metastases, or metastases to noncontiguous meninges\n\n  * Pathologic evidence of local meningeal infiltration by underlying tumor allowed\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* 18 and over\n\nPerformance status:\n\n* Karnofsky 60-100%\n\nLife expectancy:\n\n* At least 1 year\n\nHematopoietic:\n\n* Hemoglobin at least 10 g/dL\n* Absolute neutrophil count at least 1,500/mm\\^3\n* Platelet count at least 150,000/mm\\^3\n\nHepatic:\n\n* Bilirubin less than 2 times upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) less than 2 times ULN\n* Alkaline phosphatase less than 2 times ULN\n\nRenal:\n\n* Blood urea nitrogen no greater than 25 mg/dL\n* Creatinine less than 1.5 times normal\n\nPulmonary:\n\n* No pre-existing lung disease that, in the investigator's opinion, would preclude administration of carmustine or lomustine or completion of therapy\n\nOther:\n\n* No other major medical illness or psychiatric impairment that would preclude study compliance\n* No other malignancy within the past 5 years except nonmelanomatous skin cancer or carcinoma in situ of the cervix\n* No known hypersensitivity to 1 of the components of carmustine, lomustine, temozolomide, dacarbazine, or any other nitrosourea\n* No active infection\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\n* No prior biologic therapy\n\nChemotherapy:\n\n* See Disease Characteristics\n* No prior chemotherapy\n\nEndocrine therapy:\n\n* Not specified\n\nRadiotherapy:\n\n* See Disease Characteristics\n* No prior radiotherapy to brain or head and neck\n\nSurgery:\n\n* Not specified\n\nOther:\n\n* No other concurrent anticancer treatment for anaplastic astrocytoma until a recurrence is detected","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"120 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"(Phase III) Overall Survival (OS)","description":"Survival time is defined as time from randomization to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Per the protocol, the pilot arms were not included in the Phase III analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":null},{"groupId":"OG001","value":"3.8","spread":null}]}]}]},{"type":"PRIMARY","title":"(Phase I) Number of Subjects With Dose Limiting Toxicities (DLT) on the Two Pilot Arms","description":"Adverse events were graded using CTCAE v2.0. Grade refers to the severity of the adverse event (AE). The CTCAE v2.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. Dose limiting toxicity (DLT) was defined as grade 3+ pulmonary toxicity, grade 4+ thrombocytopenia (\\< 25,000 for 5 days), neutropenia (\\< 500/microl for 7 days), or neutropenia of any duration with fever requiring hospital admission after one dose reduction of 50% in BCNU. A 20% rate of grade 3+ pulmonary toxicities or a 40% rate of grade 4+ thrombocytopenia and neutropenia was considered unacceptable for a treatment arm combining RT, TMZ, and BCNU.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"(Phase III) Time to Tumor Progression (TTP)","description":"Three-year rate is reported. Progression is defined as a radiographic increase in size of the lesion by \\> 25%, recurrence of the study lesion, or the development of new lesions, confirmed by imaging. Time to tumor progression was estimated using the cumulative incidence function (CIF) on tumor progression, with death as a competing risk. Per the protocol, the pilot arms were not included in the Phase III analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.4","spread":null},{"groupId":"OG001","value":"54.7","spread":null}]}]}]},{"type":"SECONDARY","title":"(Phase III) Number of Patients With Grade 3 or Higher Toxicity","description":"Adverse events were graded using CTCAE v2.0. Grade refers to the severity of the AE. The CTCAE v2.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. The number of patients with grade or higher toxicity was calculated overall and for non-hematologic toxicity only. Per the protocol, the pilot arms were not included in the Phase III analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]}]},{"type":"SECONDARY","title":"(Phase III) Survival Time by MGMT Status","description":"Survival time is defined as time from randomization to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Tumor tissue samples were analyzed for methylation status of methyl guanine methyl transferase (MGMT), classified as methylated vs. unmethylated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":null},{"groupId":"OG001","value":"3.1","spread":null}]}]}]},{"type":"SECONDARY","title":"(Phase III) Progression-free Survival by MGMT Status","description":"Progression is defined as a radiographic increase in size of the lesion by \\> 25%, recurrence of the study lesion, or the development of new lesions, confirmed by imaging. Progression-free survival time is defined as time from randomization to date of progression or death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Tumor tissue samples were analyzed for methylation status of methyl guanine methyl transferase (MGMT), classified as methylated vs. unmethylated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"2.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":43,"n":96},"commonTop":["Fatigue","Nausea","Leukopenia NOS","Alopecia","Platelet count decreased"]}}}